An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study

This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

Inclusion Criteria:

• Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin

Exclusion Criteria:

• Patients not willing or unable to signed written consent form